Ovagen vs Selank
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
- Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Minutes (but effects persist for hours)
- Admin Route
- SubQ, Oral
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 250–500 mcg
- Frequency
- Daily for 10–30 days
- 1–3 times daily
- Key Benefits
- Hepatoprotective effects against toxic, viral, and metabolic liver damage
- Promotes hepatocyte regeneration and liver tissue repair
- May reduce liver fibrosis progression
- Supports liver metabolic function and detoxification capacity
- Anti-aging effects on hepatic tissue
- Useful in NAFLD/MASH supportive protocols
- Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
- Reduces anxiety without sedation
- Enhances memory and learning
- Improves focus and concentration
- Stabilizes mood
- Reduces physiological stress response
- May enhance motivation
- No addiction potential or withdrawal
- Fast-acting — effects within 20–30 minutes
- Approved clinically in Russia for anxiety disorders
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No clinically significant hepatotoxicity reported
- Mild sedation at higher doses (paradoxical)
- Fatigue (rare)
- Irritability during discontinuation (uncommon)
- Stacks With
- —
- —